|
1
|
Kim J, Harper A, McCormack V, Sung H,
Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I and
Fidler- Benaoudia MM: Global patterns and trends in breast cancer
incidence and mortality across 185 countries. Nat Med.
31:1154–1162. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
3
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kannan K, Sivakumar S, Venkatesan T and
Ali N: The underlying mechanisms and emerging strategies to
overcome resistance in breast cancer. Cancers (Basel). 17:29382025.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al Khzem AH, Gomaa MS, Alturki MS, Tawfeeq
N, Sarafroz M, Alonaizi SM, Al Faran A, Alrumaihi LA, Alansari FA
and Alghamdi AA: Drug repurposing for cancer treatment: A
comprehensive review. Int J Mol Sci. 25:124412024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seyyedabadi B, Babataheri S, Naseri M,
Laher I and Soraya H: Ivermectin and non-parasitic disorders: An
update. Curr Opin Pharmacol. 85:1025742025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaur B, Blavo C and Parmar MS: Ivermectin:
A multifaceted drug with a potential beyond anti-parasitic therapy.
Cureus. 16:e560252024.PubMed/NCBI
|
|
8
|
Hayashi A, Kamio K, Miyanaga A, Yoshida K,
Noro R, Matsuda K, Tozuka T, Omori M, Hirao M, Fukuizumi A, et al:
Ivermectin enhances paclitaxel efficacy by overcoming resistance
through modulation of ABCB1 in non-small cell lung cancer.
Anticancer Res. 44:5271–5282. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Zhang J, Feng Q, Jiang X, Yang Y,
Liu W, Xiao J, Feng J, Wang Z, Pan M, et al: Purinergic receptor
nanoimmunoamplifiers potentiate chemoimmunotherapy efficacy in
hepatocellular carcinoma. Biomater Res. 29:02782025. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuznetsov KO, Safina ER, Gaimakova DV,
Frolova YS, Oganesyan IY, Sadertdinova AG, Nazmieva KA, Islamgulov
AH, Karimova AR, Galimova AM and Rizvanova EV: Metformin and
malignant neoplasms: A possible mechanism of antitumor action and
prospects for use in practice. Probl Endokrinol (Mosk). 68:45–55.
2022.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song C, Jung D, Kendi AT, Rho JK, Kim EJ,
Horn I, Curran GL, Ghattamaneni S, Shim JY, Kang PS, et al:
Metformin prevents tumor cell growth and invasion of human hormone
receptor-positive breast cancer (HR+ BC) Cells via FOXA1
inhibition. Int J Mol Sci. 25:74942024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Higurashi T and Nakajima A: Metformin and
colorectal cancer. Front Endocrinol (Lausanne). 9:6222018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basheer HA, Salman NM, Abdullah RM,
Elsalem L and Afarinkia K: Metformin and glioma: Targeting
metabolic dysregulation for enhanced therapeutic outcomes. Transl
Oncol. 53:1023232025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li JH, Hsin PY, Hsiao YC, Chen BJ, Zhuang
ZY, Lee CW, Lee WJ, Vo TTT, Tseng CF, Tseng SF and Lee IT: A
narrative review: Repurposing metformin as a potential therapeutic
agent for oral cancer. Cancers (Basel). 16:30172024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng H, He L, Umar T, Wang X, Li W, Zhang
B, Zhu X, Deng G and Qiu C: Synergistic antitumor effects of
ivermectin and metformin in canine breast cancer via PI3K/AKT/mTOR
pathway inhibition. Curr Issues Mol Biol. 47:4032025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mahfauz M, Yuruker O and Kalkan R:
Repurposing metformin as a potential anticancer agent using in
silico technique. Daru. 32:549–555. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia Y, Sun M, Huang H and Jin WL: Drug
repurposing for cancer therapy. Signal Transduct Target Ther.
9:922024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ayub A, Hasan MK, Mahmud Z, Hossain MS and
Kabir Y: Dissecting the multifaceted roles of autophagy in cancer
initiation, growth, and metastasis: From molecular mechanisms to
therapeutic applications. Med Oncol. 41:1832024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Liu S, Jin L, Ma Y and Liu T: NOD2
inhibits the proliferation of esophageal adenocarcinoma cells
through autophagy. J Cancer Res Clin Oncol. 149:639–652. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Z, Han X, Ou D, Liu T, Li Z, Jiang G,
Liu J and Zhang J: Targeting PI3K/AKT/mTOR-mediated autophagy for
tumor therapy. Appl Microbiol Biotechnol. 104:575–587. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang ZM, Fang ZY, Yang X, Ji XX, Zhao YY,
Lin BY, Weng ZB and Liu EH: Glycyrrhetinic acid ameliorates gastric
mucosal injury by modulating gut microbiota and its metabolites via
Thbs1/PI3K-Akt/p53 pathway. Phytomedicine. 142:1567452025.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong S, Liang S, Cheng Z, Zhang X, Luo L,
Li L, Zhang W, Li S, Xu Q, Zhong M, et al: ROS/PI3K/Akt and
Wnt/β-catenin signalings activate HIF-1α-induced metabolic
reprogramming to impart 5-fluorouracil resistance in colorectal
cancer. J Exp Clin Cancer Res. 41:152022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsai SC, Chang PC, Lin YT, Huang PT, Chen
JY, Lin CS, Wu BN, Chang HM, Wu WJ, Chang CI and Lee CH:
Repurposing of the antipsychotic trifluoperazine induces
SLC7A11/GPX4-mediated ferroptosis of oral cancer via the
ROS/autophagy pathway. Int J Biol Sci. 20:6090–6113. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Corbella E, Fara C, Covarelli F, Porreca
V, Palmisano B, Mignogna G, Corsi A, Riminucci M, Maras B and
Mancone C: THBS1 and THBS2 enhance the in vitro proliferation,
adhesion, migration and invasion of intrahepatic cholangiocarcinoma
cells. Int J Mol Sci. 25:17822024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang M, Zhang K, Zhang Z, Zeng X, Huang
Z, Qin P, Xie Z, Cai X, Ashrafizadeh M, Tian Y and Wei R:
PI3K/AKT/mTOR axis in cancer: From pathogenesis to treatment.
MedComm (2020). 6:e702952025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bu X, Sha S, Zhang Z, Bian S, Feng S, Li
C, Wang L and Chen H: Thrombospondin 1 aggravates cardiac
remodeling in heart failure with preserved ejection fraction by
inhibiting mitophagy. iScience. 29:1146392026. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sayers EW, Beck J, Bolton EE, Brister JR,
Chan J, Connor R, Feldgarden M, Fine AM, Funk K, Hoffman J, et al:
Database resources of the National Center for Biotechnology
Information in 2025. Nucleic Acids Res. 53:D20–D29. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu A, Wang H, Lv H, Yang H, Li Y and Qian
J: Autophagy inhibitor 3-methyladenine mitigates the severity of
colitis in aged mice by inhibiting autophagy. Exp Gerontol.
201:1126972025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galicia-Moreno M, Monroy-Ramirez HC,
Caloca-Camarena F, Arceo-Orozco S, Muriel P, Sandoval-Rodriguez A,
García-Bañuelos J, García-González A, Navarro-Partida J and
Armendariz-Borunda J: A new opportunity for N-acetylcysteine. An
outline of its classic antioxidant effects and its pharmacological
potential as an epigenetic modulator in liver diseases treatment.
Naunyn Schmiedebergs Arch Pharmacol. 398:2365–2386. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cabrera-Serrano AJ, Sánchez-Maldonado JM,
González-Olmedo C, Carretero-Fernández M, Díaz-Beltrán L,
Gutiérrez-Bautista JF, García-Verdejo FJ, Gálvez-Montosa F,
López-López JA, García-Martín P, et al: Crosstalk between autophagy
and oxidative stress in hematological malignancies: Mechanisms,
implications, and therapeutic potential. Antioxidants (Basel).
14:2642025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siavoshi A, Taghizadeh M, Dookhe E and
Piran M: Gene expression profiles and pathway enrichment analysis
to identification of differentially expressed gene and signaling
pathways in epithelial ovarian cancer based on high-throughput
RNA-seq data. Genomics. 114:161–170. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang L, Fang T, Hu T, Feng J and Yan P:
Mir-338-3p targeting THBS1 attenuates glioma progression by
inhibiting the PI3K/Akt pathway. Biol Direct. 19:92024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen J, Zhou L, Ye K, Gong J, Wu F, Mo K,
Zhu Y, Chen C and Zhan R: The role of SPI1/VSIG4/THBS1 on
glioblastoma progression through modulation of the PI3K/AKT
pathway. J Adv Res. 71:487–500. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tuoheti K, Bai X, Yang L, Wang X, Cao Y,
Yisha Z, Guo L, Zhan S, Wu Z and Liu T: Forsythiaside A suppresses
renal fibrosis and partial epithelial-mesenchymal transition by
targeting THBS1 through the PI3K/AKT signaling pathway. Int
Immunopharmacol. 129:1116502024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou FL, Hu M, Hu J, Lin T and He YC:
Maslinic acid induces autophagy through PI3K/Akt/mTOR pathway in
human nasopharyngeal carcinoma cells. Chin Tradit Herb Drugs.
51:2481–2485. 2020.
|
|
36
|
Qin P, Li Q, Zu Q, Dong R and Qi Y:
Natural products targeting autophagy and apoptosis in NSCLC: a
novel therapeutic strategy. Front Oncol. 14:13796982024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xin H and Xu W: Effect of licochalcone A
on autophagy in renal cell carcinoma via PI3K/Akt/mTOR signaling
pathway. Zhongguo Zhong Yao Za Zhi. 43:3545–3552. 2018.(In
Chinese). PubMed/NCBI
|
|
38
|
Yang H, Zhou J and Yang X: Effects of
PicrosideII on autophagy of MCF-7 breast cancer cells and its
mechanism. Chin J Clin Pharmacol Ther. 24:535–540. 2019.
|
|
39
|
Malekan M, Dozandeh-Jouybari A, Joudaki N,
Ahangari M, Valadan R, Asgarian-Omran H and Taghiloo S: Inhibition
of PI3K/AKT/mTOR signaling enhances autophagy in HL-60 acute
myeloid leukemia cells: An integrative bioinformatic and in vitro
study. Biochem Biophys Rep. 44:1022202025.PubMed/NCBI
|
|
40
|
Liu Y, Cai X, Liu J, Luo Z, Zhang J, Cao
Z, Ma W, Tang Y, Liu T, Wei H and Yu CY: The role of redox
homeostasis in tumor progression: Implications for cancer therapy.
Acta Biomater. 204:156–186. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma J, Wu Y, Huang D, Zhou Y, Hou L, Li Y,
Zhong J and Wei X: Averrhoa carambola L. roots DMDD alleviates
myocardial injury in diabetes mellitus mice by regulating
ROS-mediated autophagy pathway. Chin Pharmacol Bull. 37:823–827.
2021.
|
|
42
|
Yu Y, Wang K, Zhu Y, Qi S and Luo L:
Research progress on autophagy regulated tumor radiosensitivity[J].
Journal of Xuzhou Medical University. 42:771–775. 2022.
|
![IVM combined with MET inhibits the
invasive and migratory ability of MCF-7 cells. (A) Representative
Transwell images and (B) quantification of the invasive ability of
MCF-7 cells. (C) Representative scratch images and (D)
quantification of the migration ability in [Ctrl, IVM (6 µM), MET
(6 mM), and IVM + MET] groups of MCF-7 cells. IVM, ivermectin; MET,
metformin, MCF-7, human mammary tumor cell line; Ctrl, control. All
data were measured as mean ± SEM by three independent experiments.
**P<0.01.](/article_images/or/56/1/or-56-01-09136-g01.jpg)
